Streetbeat News

Regulatory

GOVX

GeoVax has been issued a patent titled 'Replication-Deficient Modified Vaccinia Ankara (MVA) And Matrix Protein (VP40)' by the U.S. Patent and Trademark Office. The patent number is 11,701,418 B2.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2023 | 1:02 pm

GSK

PFE

ViiV Healthcare, majority owned by GSK plc and Pfizer Inc, has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use, recommending marketing authorization for cabotegravir long-acting (LA) injectable and tablets for HIV prevention. The positive opinion is supported by data from two international phase 2b/3 studies, HPTN 083 and HPTN 084.

Portfolio Pulse from Vandana Singh

July 24, 2023 | 12:56 pm

BCDA

Biocardia's shares are trading lower after the Independent Data Safety Monitoring Board recommended the company to pause enrollment in its ongoing Phase 3 CardiAMP Cell Therapy Heart Failure Trial.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2023 | 12:49 pm

CNEY

CN Energy Group. Inc. (NASDAQ: CNEY) has been granted an additional 180-day period by NASDAQ to regain compliance under NASDAQ's minimum bid price requirement. The company's Class A ordinary shares need to close at $1.00 or more for a minimum of 10 consecutive business days by January 8, 2024. The company may consider implementing a reverse share split to meet the requirement.

Portfolio Pulse from Happy Mohamed

July 24, 2023 | 12:38 pm

CEI

Camber Energy's majority-owned subsidiary, Viking Energy Group, announced that its subsidiary, Viking Protection Systems, received a Notice of Allowance from the USPTO for a utility patent application for 'Electric Transmission Line Ground Fault Prevention Systems Using Dual, High Sensitivity Monitoring'. This prospective patent is in addition to another one announced by Viking on May 30, 2023. The technology is designed to improve the resiliency and reliability of existing infrastructure.

Portfolio Pulse from Happy Mohamed

July 24, 2023 | 12:37 pm

GILD

Gilead Sciences Inc has decided to discontinue the Phase 3 ENHANCE study in higher-risk myelodysplastic syndromes (MDS) due to futility based on a planned analysis. The study evaluated the combination of magrolimab plus azacitidine as first-line treatments for higher-risk MDS. The FDA had previously placed a partial clinical hold on the study due to suspected unexpected serious adverse reactions, but lifted the hold in April. Gilead is working on next steps for patients enrolled in the study.

Portfolio Pulse from Vandana Singh

July 24, 2023 | 12:36 pm

TMC

The Metals Company (TMC) has commented on the International Seabed Authority (ISA) Council's decision to continue the development of rules, regulations, and procedures (RRPs) for seafloor resource exploitation. TMC's subsidiary, Nauru Ocean Resources Inc. (NORI), plans to submit an application for a plan of work for exploitation once these RRPs are in place. TMC's CEO, Gerard Barron, expressed disappointment at the delay in adopting the RRPs but remains optimistic about the future of commercial-scale nodule collection.

Portfolio Pulse from Happy Mohamed

July 24, 2023 | 12:36 pm

ABBV

AbbVie has announced the first patient dosing in a global Phase 3 trial of upadacitinib for the treatment of moderate to severe hidradenitis suppurativa (HS), a chronic, inflammatory disease with limited therapeutic options. The trial, named Step-Up HS, is the first registered, randomized Phase 3 trial in HS and aims to enroll approximately 1,300 participants across 275 sites worldwide. The primary endpoint will measure the percentage of participants achieving a 50% reduction in the total abscess and inflammatory nodule count with no increase in abscess count and no increase in draining fistula count relative to baseline at week 16.

Portfolio Pulse from Happy Mohamed

July 24, 2023 | 12:33 pm

DYAI

Dyadic has completed dosing of patients for its recombinant protein RBD vaccine candidate, with no major safety concerns or serious adverse events reported. The vaccine produced an immune response at both dose levels. A full study report is expected in Q4, 2023.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2023 | 12:31 pm

SPY

The USA Chicago Fed National Activity for June came in at -0.32, lower than the estimated 0.03 and the prior figure of -0.15.

Portfolio Pulse from Happy Mohamed

July 24, 2023 | 12:30 pm